Literature DB >> 15940491

[Management of pulmonary embolism].

B Schmidt1, S Schellong.   

Abstract

Venous thromboembolism is often triggered by transient episodes of increased risk but may occur spontaneously in patients with permanently increased risk. Pulmonary embolism may cause impairment of respiratory and circulatory function which can vary in severity from silent to catastrophic. The diagnosis can be feasibly established by detecting vein thrombosis. If this approach fails, demonstration of pulmonary emboli by lung scans becomes necessary to establish the diagnosis. A D-dimer-test can select patients in whom imaging of pulmonary perfusion is required. Immediate therapeutic anticoagulation with heparins is mandatory in confirmed thromboembolism, and is followed by a vitamin K antagonist. In the initial work-up, patients also have to be evaluated for systemic thrombolytic therapy by hemodynamic parameters and echocardiography. In a triggered episode of venous thromboembolism, duration of anticoagulation is confined to several months while spontaneous or recurrent events require prolonged or indefinite treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940491     DOI: 10.1007/s00108-005-1422-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

1.  Contribution of noninvasive evaluation to the diagnosis of pulmonary embolism in hospitalized patients.

Authors:  M J Miron; A Perrier; H Bounameaux; P de Moerloose; D O Slosman; D Didier; A Junod
Journal:  Eur Respir J       Date:  1999-06       Impact factor: 16.671

2.  The low-probability lung scan. A need for change in nomenclature.

Authors:  R D Hull; G E Raskob; G F Pineo; R F Brant
Journal:  Arch Intern Med       Date:  1995-09-25

Review 3.  The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism.

Authors:  C Kearon; J S Ginsberg; J Hirsh
Journal:  Ann Intern Med       Date:  1998-12-15       Impact factor: 25.391

4.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; S Granqvist; M Holmström; A Carlsson; P Lindmarker; P Nicol; S G Eklund; S Nordlander; G Lärfars; B Leijd; O Linder; E Loogna
Journal:  N Engl J Med       Date:  1997-02-06       Impact factor: 91.245

5.  Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism.

Authors:  Nils Kucher; Gert Printzen; Tanja Doernhoefer; Stephan Windecker; Bernhard Meier; Otto Martin Hess
Journal:  Circulation       Date:  2003-03-24       Impact factor: 29.690

Review 6.  Diagnostic strategies for suspected pulmonary embolism.

Authors:  A B Donkers-van Rossum
Journal:  Eur Respir J       Date:  2001-09       Impact factor: 16.671

7.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.

Authors:  R J Beyth; L M Quinn; C S Landefeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

Review 8.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Harry R Büller; Giancarlo Agnelli; Russel D Hull; Thomas M Hyers; Martin H Prins; Gary E Raskob
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis.

Authors:  Sebastian M Schellong; Thomas Schwarz; Kai Halbritter; Jan Beyer; Gabriele Siegert; Wolfram Oettler; Benjamin Schmidt; Hans E Schroeder
Journal:  Thromb Haemost       Date:  2003-02       Impact factor: 5.249

Review 10.  D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review.

Authors:  Paul D Stein; Russell D Hull; Kalpesh C Patel; Ronald E Olson; William A Ghali; Rollin Brant; Rita K Biel; Vinay Bharadia; Neeraj K Kalra
Journal:  Ann Intern Med       Date:  2004-04-20       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.